Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 15493031)

1.

Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay.

Lofgren ET, Cole SR, Weber DJ, Anderson DJ, Moehring RW.

Epidemiology. 2014 Jul;25(4):570-5. doi: 10.1097/EDE.0000000000000119.

2.

Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals.

Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A.

AIDS. 2014 Jan 14;28(2):257-65. doi: 10.1097/QAD.0000000000000078.

3.

When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.

Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA.

Int J Biostat. 2010;6(2):Article 18.

4.

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

Writing Committee for the CASCADE Collaboration.

Arch Intern Med. 2011 Sep 26;171(17):1560-9. doi: 10.1001/archinternmed.2011.401.

5.

Left truncation, susceptibility, and bias in occupational cohort studies.

Applebaum KM, Malloy EJ, Eisen EA.

Epidemiology. 2011 Jul;22(4):599-606. doi: 10.1097/EDE.0b013e31821d0879.

6.

Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.

Lifson AR, Krantz EM, Eberly LE, Dolan MJ, Marconi VC, Weintrob AC, Crum-Cianflone NF, Ganesan A, Grambsch PL, Agan BK; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group.

AIDS Res Ther. 2011 Jan 18;8(1):2. doi: 10.1186/1742-6405-8-2.

7.

When should antiretroviral therapy be started in HIV-positive persons?

Sabin CA.

F1000 Med Rep. 2010 Nov 24;2:81. doi: 10.3410/M2-81.

8.

Nonparametric tests for right-censored data with biased sampling.

Ning J, Qin J, Shen Y.

J R Stat Soc Series B Stat Methodol. 2010 Nov 1;72(5):609-630.

9.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, Ive P, Rassool M, Dehlinger M, van der Horst C, McIntyre J, Wood R.

AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.

10.

Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy.

Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR.

Epidemiology. 2010 Sep;21(5):698-705. doi: 10.1097/EDE.0b013e3181e97737.

11.

Inference for mutually exclusive competing events through a mixture of generalized gamma distributions.

Checkley W, Brower RG, Muñoz A; NIH Acute Respiratory Distress Syndrome Network Investigators.

Epidemiology. 2010 Jul;21(4):557-65. doi: 10.1097/EDE.0b013e3181e090ed.

12.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR.

Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Review.

13.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD; NA-ACCORD Investigators.

N Engl J Med. 2009 Apr 30;360(18):1815-26. doi: 10.1056/NEJMoa0807252. Epub 2009 Apr 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk